Suchergebnisse - "Asselah, Tarik"

PubPharm (95)

1

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon : a long-term follow-up study

enthalten in: Journal of hepatology | 2009

von Moucari, R. | Korevaar, A. | Lada, O. | +11

2

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

enthalten in: Journal of hepatology | 2009

von Moucari, R. | Korevaar, A. | Lada, O. | +11

3

Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2009

von Maylin, S. | Martinot-Peignoux, M. | Ripault, M. | +9

CommentIn: Liver Int. 2009 Apr;29(4):481-2. - PMID 19323778

4

Early serum HBsAg drop : a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

enthalten in: Hepatology (Baltimore, Md.) | 2009

von Moucari, R. | Mackiewicz, V. | Lada, O. | +11

CommentIn: Hepatology. 2009 Apr;49(4):1063-5. - PMID 19330864

5

Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin

enthalten in: Antiviral therapy | 2009

von Martinot-Peignoux, M. | Maylin, S. | Moucari, R. | +11

6

Protease and polymerase inhibitors for the treatment of hepatitis C

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2009

von Asselah, T. | Benhamou, Y. | Marcellin, P.

7

Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody

enthalten in: Liver international | 2009

von Maylin, S. | Martinot-Peignoux, M. | Ripault, M. | +9

8

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patientsPotential conflict of interest: Dr. Marcellin advises, is a consultant for, and is on the speakers&apos: bureau of Roche, Schering-Plough, Gilead, Bristol-Myers Squibb, GlaxoSmithKline, and Idenix-Novartis. He is a consultant for and advises Vertex, Valeant, Human Genome Sciences, Cythesis, Intermune, Wyeth, and Tibotec. He also advises Coley Pharma.

enthalten in: Hepatology | 2009

von Moucari, R. | Mackiewicz, V. | Lada, O. | +11

9

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

enthalten in: Journal of hepatology | 2009

von Moucari, R. | Korevaar, A. | Lada, O. | +11

10

Clevudine : a promising therapy for the treatment of chronic hepatitis B

enthalten in: Expert opinion on investigational drugs | 2008

von Asselah, T. | Lada, O. | Moucari, R. | +1

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]